广西≥50岁男性新报告人类免疫缺陷病毒感染者的基因亚型及治疗前耐药分析
Genetic Subtypes and Pretreatment Drug Resistance in the Newly Reported Human Immunodeficiency Virus-Infected Men Aged≥50 Years Old in Guangxi
查看参考文献16篇
|
文摘
|
目的分析广西≥50岁男性新报告人类免疫缺陷病毒(HIV)感染者的基因亚型及治疗前耐药情况。方法采用分层随机抽样法,选取广西14个城市2020年1至6月新报告≥50岁男性HIV感染者,采用巢式逆转录聚合酶链反应扩增HIV-1pol基因片段进行测序,分析耐药突变位点及耐药程度。结果共615例HIV感染者纳入分析,CRF01_ AE、CRF07_ BC和CRF08_ BC 3种主要亚型的构成比分别为57.4% (353/615)、17.1% (105/615)和22.4% (138/615)。核苷逆转录酶抑制剂(NRTI)、非NRTI (NNRTI)和蛋白酶抑制剂发生耐药位点突变例数分别为8例(1.3%)、18例(2.9%)和0例。NRTI和NNRTI位点突变率最高的分别为M184V (0.7%)和K103N (1.8%)。22例(3.6%)至少对任意一类逆转录酶抑制剂产生耐药,其中,对NRTI耐药4例(0.7%)、NNRTI耐药14例(2.3%),同时产生耐药4例(0.7%);对蛋白酶抑制剂未产生耐药。NNRTI治疗前耐药率高于NRTI (2.9% 比1.3%;χ~2= 3.929,P = 0.047)。拉米夫定、齐多夫定、替诺福韦、阿巴卡韦、利匹韦林、依非韦伦、奈韦拉平和洛匹那韦/利托那韦的治疗前耐药所占比例分别为0.8%、0.3%、0.7%、1.0%、1.3%、2.8%、2.9%和0。结论CRF01_AE、CRF07_ BC和CRF08_ BC为2020年广西新报告≥50岁男性HIV感染者主要流行毒株,其治疗前耐药仍处于低度流行水平。 |
|
其他语种文摘
|
Objective To analyze the genetic subtypes of human immunodeficiency virus (HIV) and the prevalence of pretreatment drug resistance in the newly reported HIV-infected men in Guangxi.Methods The stratified random sampling method was employed to select the newly reported HIV-infected men aged≥50 years old in 14 cities of Guangxi from January to June in 2020.The pol gene of HIV-1 was amplified by nested reverse transcription polymerase chain reaction and then sequenced.The mutation sites associated with drug resistance and the degree of drug resistance were then analyzed.Results A total of 615 HIV-infected men were included in the study.The genetic subtypes of CRF01_ AE,CRF07_ BC,and CRF08_ BC accounted for 57.4% (353/615),17.1% (105/615),and 22.4% (138/615),respectively.The mutations associated with the resistance to nucleoside reverse transcriptase inhibitors (NRTI),non-nucleoside reverse transcriptase inhibitors (NNRTI),and protease inhibitors occurred in 8 (1.3%),18 (2.9%),and 0 patients,respectively.M184V (0.7%) and K103N (1.8%) were the mutations with the highest occurrence rates for the resistance to NRTIs and NNRTIs,respectively.Twenty-two (3.6%) patients were resistant to at least one type of inhibitors.Specifically,4 (0.7%),14 (2.3%),4 (0.7%),and 0 patients were resistant to NRTIs,NNRTIs,both NRTIs and NNRTIs,and protease inhibitors,respectively.The pretreatment resistance to NNRTIs had much higher frequency than that to NRTIs (2.9% vs.1.3%;χ~2 = 3.929,P = 0.047).The prevalence of pretreatment resistance to lamivudine,zidovudine,tenofovir,abacavir,rilpivirine,efavirenz,nevirapine,and lopinavir/ritonavir was 0.8%,0.3%,0.7%,1.0%,1.3%,2.8%,2.9%,and 0,respectively.Conclusions CRF01_ AE,CRF07_ BC,and CRF08_ BC are the three major strains of HIV-infected men≥50 years old newly reported in Guangxi,2020,and the pretreatment drug resistance demonstrates low prevalence. |
|
来源
|
中国医学科学院学报
,2023,45(3):399-404 【核心库】
|
|
DOI
|
10.3881/j.issn.1000-503X.15444
|
|
关键词
|
人类免疫缺陷病毒
;
基因亚型
;
治疗前耐药
|
|
地址
|
1.
广西壮族自治区疾病预防控制中心艾滋病防制所, 南宁, 530028
2.
贵港市疾病预防控制中心检验科, 广西, 贵港, 537100
3.
南宁市疾病预防控制中心性病艾滋病防制科, 南宁, 530023
4.
柳州市疾病预防控制中心艾滋病防制所, 广西, 柳州, 545007
5.
桂林市疾病预防控制中心性病艾滋病防制科, 广西, 桂林, 541001
|
|
语种
|
中文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1000-503X |
|
学科
|
预防医学、卫生学 |
|
基金
|
广西重点研发计划
;
广西自然科学基金
;
广西艾滋病防控与成果转化研究重点实验
;
广西八桂学者艾滋病防控关键技术岗位专项
;
广西医疗卫生重点学科建设项目
|
|
文献收藏号
|
CSCD:7524764
|
参考文献 共
16
共1页
|
|
1.
葛宪民. 广西壮族自治区2010-2017年艾滋病流行病学特征分析.
中华流行病学杂志,2019,40(3):315-321
|
CSCD被引
18
次
|
|
|
|
|
2.
葛宪民. 广西灵山县人类免疫缺陷病毒阳性孕产妇接受抗逆转录病毒治疗预防母婴传播后对18月龄儿童生长发育的影响.
中国医学科学院学报,2021,43(5):743-748
|
CSCD被引
1
次
|
|
|
|
|
3.
Chen H. Rapidly spreading human immunodeficiency virus epidemic among older males and associated factors: a large-scale prospective cohort study in rural southwest China.
Sex Transm Dis,2019,46(4):234-239
|
CSCD被引
3
次
|
|
|
|
|
4.
World Health Organization.
Surveillance of HIV drug resistance in populations initiating antiretroviral therapy (pre-treatment HIV drug resistance): concept note,2022
|
CSCD被引
1
次
|
|
|
|
|
5.
Wittkop L. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.
Lancet Infect Dis,2011,11(5):363-371
|
CSCD被引
11
次
|
|
|
|
|
6.
Zhong P. Genetic diversity and drug resistance of human immunodeficiency virus type 1 (HIV-1) strains circulating in Shanghai.
AIDS Res Hum Retroviruses,2007,23(7):847-856
|
CSCD被引
26
次
|
|
|
|
|
7.
Feng Y. The rapidly expanding CRF01_ AE epidemic in China is driven by multiple lineages of HIV-1 viruses introduced in the 1990s.
AIDS,2013,27(11):1793-1802
|
CSCD被引
34
次
|
|
|
|
|
8.
李剑军. 广西HIV-1分子流行病学20年.
应用预防医学,2017,23(2):173-176
|
CSCD被引
6
次
|
|
|
|
|
9.
Zhang J. Genetic characteristics of CRF01_ AE among newly diagnosed HIV-1-infected 16-to 25-year olds in 3 geographic regions of Guangxi,China.
Medicine (Baltimore),2015,94(21):e894
|
CSCD被引
4
次
|
|
|
|
|
10.
曹志强. 广西钦州市2016-2018年新报告HIV感染者不同基因型首次CD4~+ T细胞计数分析.
中国热带医学,2020,20(5):397-401
|
CSCD被引
4
次
|
|
|
|
|
11.
Xu X. Survey of pretreatment HIV drug resistance and the genetic transmission networks among HIV-positive individuals in southwestern China,2014-2020.
BMC Infect Dis,2021,21(1):1153
|
CSCD被引
1
次
|
|
|
|
|
12.
World Health Organization.
Guidelines on the public health response topretreatment HIV drug resistance: July 2017,2022
|
CSCD被引
1
次
|
|
|
|
|
13.
Li R. Prevalence of transmitted drug resistance among ART-naive HIV-infected individuals,Beijing, 2015-2018.
J Glob Antimicrob Resist,2022,28:241-248
|
CSCD被引
2
次
|
|
|
|
|
14.
Kang R H. Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017.
Infect Dis Poverty,2020,9(1):54
|
CSCD被引
14
次
|
|
|
|
|
15.
Liu L. Survey of pretreatment HIV drug resistance and genetic transmission network analysis among HIV patients in a high drug-use area of southwest China.
Curr HIV Res,2019,17(6):441-451
|
CSCD被引
3
次
|
|
|
|
|
16.
中华医学会感染病学分会艾滋病丙型肝炎学组. 中国艾滋病诊疗指南(2021年版).
中国艾滋病性病,2021,27(11):1182-1201
|
CSCD被引
47
次
|
|
|
|
|
了解气象卫星更多信息，请访问